MORE►
Secretome Therapeutics
Illustration: Michael Samples
North Texas’ Secretome Therapeutics Raises $30M Series A to Advance Muscular Dystrophy-Related Drug
by Sandra Engelland | May 28, 2026
The financing from Boston's RA Capital Management will support company operations and the continued development of Secretome’s pipeline of innovative treatments, including STM-01, an nCPC-derived therapy in development for treating Duchenne muscular dystrophy, which has had few therapeutic options.
by Lance Murray |
Apr 23, 2025
Michelle Smith Warren, MD, is a highly experienced pharmaceutical executive with more than two decades of leadership in clinical development, translational medicine, and regulatory strategy across multiple therapeutic areas, including cell therapy, immunology, cardiovascular, and rare diseases, Secretome said.
MORE►
by Lance Murray |
Dec 9, 2024
Baltimore-based Secretome—which has a presence at BioLabs at Pegasus Park in Dallas and offices in Plano—said the financing will enable it to initiate clinical trials for its lead asset, STM-01, and further advance its drug development pipeline.
MORE►
by Lance Murray |
Sep 17, 2024
Baltimore-based Secretome has a presence at BioLabs at Pegasus Park in Dallas. The biotech company is at the forefront of developing "revolutionary solutions" aimed at harnessing the power of secretomes, naturally occurring molecules that promote healing and regeneration, HEST said.
MORE►
Secretome Therapeutics Appoints Financial Veteran as CFO
by Lance Murray | Aug 3, 2023
Dallas-based Secretome Therapeutics announced that Deepa Prasad has been appointed chief financial officer of the biotechnology company, which develops first-in-class therapeutics derived from neonatal mesenchymal stem cells for the treatment of underserved diseases.
“Deepa brings a wealth of knowledge through her combination of investment banking, operations, and venture capital experience in the life science industry,” Vinny Jindal, president and chief executive officer of Secretome Therapeutics, said in a statement....
MORE►
by Lance Murray |
Jul 20, 2023
Secretome Therapeutics, a Dallas-based biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells, has appointed Margot Connor to its board of directors and announced the appointment of its clinical advisory board composed of world-class clinicians and researchers in the field of heart failure.
“I have been fortunate to be part of the stem cell-based therapy evolution, and I believe secretomes are a true breakthrough in this extraordinary field,” Connor said in a statement....
MORE►
